TATA CAPITAL LTD: ₹825.00 (0.00%)     TATA REFRACTORIES LTD - KROSAKI: ₹1775.00 (0.00%)     HERO FINCORP LTD: ₹1375.00 (0.00%)     SBI MUTUAL FUNDS LTD: ₹2775.00 (0.00%)     NATIONAL STOCK EXCHANGE: ₹2075.00 ▼ (-0.95%)     POLYMATECH ELECTRONICS LTD: ₹75.00 ▲ (4.17%)     HDFC SECURITIES LTD: ₹10500.00 (0.00%)     CHENNAI SUPER KINGS LTD: ₹185.00 (0.00%)     CAPGEMINI TECHNOLOGY SERVICES: ₹11250.00 ▼ (-2.17%)     STERLITE GRID 5 UNLISTED SHARES: ₹365.00 (0.00%)     MOHAN MEAKIN LTD: ₹2195.00 (0.00%)     MANJUSHREE TECNHOPACK INDIA LTD: ₹1025.00 (0.00%)     SPRAY ENGINEERING DEVICES LTD: ₹305.00 (0.00%)     DEEPAK HOUSEWARE AND TOYS: ₹65.00 ▼ (-4.41%)     KURLON ENTERPRISE LIMITED: ₹450.00 (0.00%)     DELTA GALAXY ENGINEERING SERVICES: ₹49.00 (0.00%)     INDIAN POTASH LTD: ₹3250.00 ▼ (-4.41%)     NCL BUILDTEK LTD: ₹235.00 (0.00%)     OYO HOTELS LTD: ₹47.00 ▲ (17.50%)     ORBIS FINANCIALS CORPORATION LTD: ₹525.00 (0.00%)     APOLLO GREEN ENERGY LTD: ₹108.00 ▼ (-0.92%)     OTIS ELEVATORS COMPANY INDIA LTD: ₹3750.00 (0.00%)     STERLITE POWER TRANSMISSION LTD: ₹575.00 (0.00%)     UTKARSH MICRO FINANCE LTD: ₹205.00 (0.00%)     MERINO LAMINATES LTD: ₹3250.00 (0.00%)     CARRIER AIRCONDITIONING & REFRIGERATION: ₹495.00 (0.00%)     GREENZO ENERGY INDIA LTD: ₹665.00 (0.00%)     VEEDA CHEMICAL RESEARCH LTD: ₹475.00 (0.00%)     STUDDS ACCESSORIES LTD: ₹635.00 (0.00%)     API HOLDINGS LTD: ₹7.25 (0.00%)     NCDEX: ₹345.00 (0.00%)     COCHIN INTERNATIONAL AIRPORT LTD: ₹475.00 (0.00%)     MATRIX GAS AND RENEWABLES LTD: ₹32.00 ▼ (-5.88%)     GOODLUCK DEFENCE & AEROSPACE LTD: ₹318.00 (0.00%)     B9 BEVERAGES LTD: ₹305.00 (0.00%)     DALMIA BHARAT REFRACTORIES LTD: ₹255.00 (0.00%)     IMAGINE MARKETING LTD: ₹1425.00 ▼ (-1.72%)     CARE HEALTH LTD: ₹149.00 (0.00%)     LAVA INTERNATIONAL LTD: ₹42.00 ▲ (10.53%)     HINDUJA LEYLAND FINANCE LIMITED: ₹245.00 ▲ (2.08%)     PHILIPS LIGHTING SIGNIFY INNOVATIONS: ₹1275.00 (0.00%)     ASK INVESTMENT MANAGERS LIMITED: ₹1275.00 (0.00%)     STERLITE ELECTRIC LTD: ₹530.00 (0.00%)     VCI CHEMICALS INDUSTRIES: ₹60.00 (0.00%)     PARAG PARIKH FINANCIAL ADVISORY SERVICES LTD: ₹14750.00 ▲ (3.51%)     HELLA INFERA MARKET PRIVATE LIMITED: ₹210000.00 (0.00%)     NAYARA ENERGY LIMITED: ₹1250.00 (0.00%)     INNOV8 WORKSPACES INDIA LIMITED: ₹52.00 (0.00%)     PACE DIGITEK INFRA PRIVATE LIMITED: ₹225.00 ▲ (9.76%)     POWER EXCHANGE INDIA LIMITED: ₹575.00 ▲ (1.77%)     GFCL EV PRODUCTS LIMITED: ₹52.00 (0.00%)    
VEEDA CHEMICAL RESEARCH LTD Logo

VEEDA CHEMICAL RESEARCH LTD

Last Traded Price

₹475.00 ( 0.00 % )

Principles

Company Name

VEEDA CHEMICAL RESEARCH LTD


ISIN No.

INE01HQ01026


No. of Outstanding Shares

62999846


PAN No.

AACCC3633Q


Face Value

₹ 2.00


EPS

₹-0.06


PE ratio

None


P/S Ratio

7.10


Market Capitalization (in Cr)

₹2897.99


Book value

₹168.25


P/BV

2.73


DRHP Filed?

No


Available on

nsdl/cdsl


Sector

CLINICAL RESEARCH


CIN

U73100GJ2004PLC044023


Registration Date

Aug. 14, 2008


Stock Performance

Stock Price Over Time

Share Details

Company Snapshot

Veeda Clinical Research is one of India’s leading independent CROs, distinguished by robust regulatory credentials, expanding global footprint through acquisitions/JVs, and a strong revenue base, now gearing up for a major IPO to fund further growth.

Veeda is a full-service Clinical Research Organization (CRO) headquartered in Ahmedabad, offering end-to-end services across the drug development lifecycle:

  • Preclinical and non-clinical studies
  • Healthy volunteer (HVS), bioavailability, and bioequivalence trials
  • Early- to late-phase (Phase I–IV) clinical trials
  • Bioanalytical testing, including large-molecule assays

Global Reach & Capabilities

  • Regulatory Compliance: Passed 119 global inspections (including US FDA, MHRA, ANVISA, WHO).
  • Facilities: Operates seven facilities in India, located in Ahmedabad, Mehsana, and Bangalore.

Growth & Strategic Moves

  • 2024: Acquired European oncology-focused CRO Heads, enhancing global trial capabilities.
  • Acquired majority stake in Bengaluru-based preclinical CRO Bioneeds.
  • 2021: Joint venture with Somru BioScience to launch Ingenuity BioSciences in Ahmedabad.

Industry Outlook

Market Size & Growth

  • 1. Clinical CRO Market:
    • USD 2,501.7 million in 2024 (~₹20,850 crore)
    • Expected to reach USD 4,410 million (~₹36,800 crore) by 2030 (CAGR 9.9%)
  • 2. Overall CRO Market (incl. preclinical):
    • USD 0.73 billion in 2024 (~₹6,070 crore)
    • Expected to grow to USD 1.32 billion (~₹10,980 crore) by 2032 (CAGR ~7.2%)

Key Growth Drivers

  • Cost competitiveness: Trials in India cost 30–50% less than in the West.
  • Large patient population: Enables faster enrollment and diverse studies.
  • Regulatory reforms: 2019 rules have halved approval timelines.
  • Digital transformation: Use of AI, EDC, remote monitoring, and decentralized trials is increasing efficiency.
  • Therapeutic expansion: Increasing trials in oncology, rare diseases, and biologics.

Summary

  • Short-term (1–3 years): Growth in clinical and preclinical services, boosted by tech and regulation.
  • Mid-term (3–7 years): Expansion into biologics and CDMO integration.
  • Long-term (by 2030): CRO + CDMO revenue potential of ₹1.8 lakh crore (~$25 billion globally).

India's CRO industry is entering a maturing phase, well-positioned to serve global sponsors through a mix of cost leadership, regulatory strength, and tech adoption.

Latest Shareholding Pattern of Veeda Clinical Research Ltd.

Shareholder Holding (%)
Basil Private Limited 35.52%
Bondway Investments Inc 20.45%
Sabre Partners AIF Trust 4.38%
Others (including individuals) 39.65%